Treats acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. ANDA 72945, held by Hospira. Cytarabine.
As of Nov 16, 2026, ANDA 72945 (Cytarabine), held by Hospira, was first approved by FDA on Feb 28, 1994, with 13 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine20MG/ML · injectable;injection | Cytarabine | Rx |
| Aug 3, 2026 | Supplement 31Labeling · Standard review | Approved | None posted |
| Jun 2, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Jan 15, 2019 | Supplement 24Labeling · Standard review | Approved | None posted |
| Oct 3, 2018 | Supplement 20Manufacturing | Approved | None posted |
| Oct 3, 2018 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 18, 2003 | Supplement 12Labeling | Approved | None posted |
| May 14, 2001 | Supplement 10Manufacturing | Approved | None posted |
| Aug 8, 2000 | Supplement 8Manufacturing | Approved | None posted |
| May 18, 2000 | Supplement 7Manufacturing | Approved | None posted |
| May 12, 2000 | Supplement 6Manufacturing | Approved | None posted |
| Jun 3, 1997 | Supplement 3Labeling | Approved | None posted |
| Apr 28, 1995 | Supplement 2Manufacturing | Approved | None posted |
| Sep 21, 1994 | Supplement 1Labeling | Approved | None posted |
| Feb 28, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters